Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00451763
Status:
COMPLETED
Last Update Posted:
2008-07-23
First Post:
2007-03-21
Brief Title:
Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia
Sponsor:
University of Sao Paulo
Organization:
University of Sao Paulo
Study Overview
Official Title:
Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia
Status:
COMPLETED
Status Verified Date:
2007-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Idiopathic Macular Telangiectasia is characterized by incompetent and dilated retinal capillaries in the foveolar region of unknown cause for retinal telangiectasia
In Idiopathic Macular Telangiectasia proliferative changes occur in the deep retinal capillary network leading to intraretinal neovascularization that unlike in age-related macular degeneration seems to be retinal rather than choroidal in origin Before the hemorrhagic and fibrotic state these vessels may lead to exudation and decrease in the visual acuity Long-term visual prognosis in patients with this complication may be poor and treatment with laser photocoagulation is unproven Although newly reported treatment by photodynamic therapy for neovascular membrane associated with Idiopathic Macular Telangiectasia may show vision and angiographic stability in a few cases the improvement may be transient VEGF has been implicated as the major angiogenic stimulus responsible for neovascularization in AMD ensuing specific anti-VEGF treatment in these cases
The purpose of the study is to evaluate intravitreal injection of bevacizumab 125mg005ml in the treatment of Idiopathic Macular Telangiectasia
In Idiopathic Macular Telangiectasia proliferative changes occur in the deep retinal capillary network leading to intraretinal neovascularization that unlike in age-related macular degeneration seems to be retinal rather than choroidal in origin Before the hemorrhagic and fibrotic state these vessels may lead to exudation and decrease in the visual acuity Long-term visual prognosis in patients with this complication may be poor and treatment with laser photocoagulation is unproven Although newly reported treatment by photodynamic therapy for neovascular membrane associated with Idiopathic Macular Telangiectasia may show vision and angiographic stability in a few cases the improvement may be transient VEGF has been implicated as the major angiogenic stimulus responsible for neovascularization in AMD ensuing specific anti-VEGF treatment in these cases
The purpose of the study is to evaluate intravitreal injection of bevacizumab 125mg005ml in the treatment of Idiopathic Macular Telangiectasia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None